Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
Information source: Wills Eye
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: bevacizumab (Drug); balanced salt solution (Other)
Phase: Phase 2/Phase 3
Status: Completed
Sponsored by: Wills Eye Official(s) and/or principal investigator(s): Marlene R Moster, MD, Principal Investigator, Affiliation: Wills Eye
Summary
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma
surgery improves the success of needle bleb revisions.
Clinical Details
Official title: Does a New Add on (or Adjunctive) Therapy Used in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Intraocular Pressure (IOP)
Secondary outcome: Improvement in Filtering Blebs Morphology
Detailed description:
To investigate the efficacy of needle bleb revisions with mitomycin C with subconjunctival
bevacizumab in promoting both filtering success and favorable bleb morphologic features.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- require glaucoma bleb needle revision with Mitomycin-C
Exclusion Criteria:
- pregnant, nursing, or not using adequate contraception
- other glaucoma eye surgery involving tube shunts
- prior retinal detachments surgery with scleral buckle
- infection, inflammation, or any abnormality preventing eye pressure measurement
- enrolled in another investigational study
Locations and Contacts
Wills Eye Institute, Glaucoma Service, Philadelphia, Pennsylvania 19107, United States
Additional Information
Starting date: February 2009
Last updated: March 11, 2015
|